On Puberty Blockers, FDA Is In ‘Listen Only’ Mode – For Now

Commissioner Califf’s agreement to a briefing from the Endocrine Society on the research related to puberty-delaying medicines for gender dysphoria in children and adolescents may signal the agency’s acknowledgement of the importance of the topic, which gets into broader issues surrounding FDA’s role in off-label use.